MedTrace Logo

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

NCT01287793 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2011-05-24

No results posted yet for this study

Summary

Administration of a single 50 mg or 200 mg dose of tigecycline will not cause a change in QT/QTc intervals.

Conditions

  • Healthy

Interventions

DRUG

tigecycline

intravenous, 200 mg, single dose

DRUG

tigecycline

intravenous, 50 mg, single dose

DRUG

moxifloxacin

oral tablet, 400 mg, single dose

DRUG

100 mL 0.9% Sodium Chloride intravenous

intravenous fluid, 100 mL, single dose

DRUG

placebo

0.9% Sodium Chloride intravenous 100mL, single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01287793 on ClinicalTrials.gov